Filter
67
Filtered Results: 67
Text search:
Drugs
for
neglected
diseases
initiative
DNDi
Featured
Recommendations
8
New Publications
6
Language
Document type
Studies & Reports
24
No document type
15
Strategic & Response Plan
6
Manuals
5
Resource Platforms
5
Guidelines
3
Videos
3
Fact sheets
3
Infographics
2
Situation Updates
1
Countries / Regions
Global
10
Latin America and the Carribbean
5
Colombia
3
Africa
3
Ethiopia
3
Kenya
2
West and Central Africa
2
East and Southern Africa
2
Southern Africa
2
Asia
1
Bangladesh
1
Uganda
1
Brazil
1
India
1
Authors & Publishers
Publication Years
Category
Countries
13
Clinical Guidelines
9
Pharmacy & Technologies
3
Public Health
1
Toolboxes
NTDs
42
HIV
3
Global Health Education
3
COVID-19
2
Pharmacy
2
TB
1
Health Financing Toolbox
1
NCDs
1
AMR
1
Not long ago, on the occasion of the 100th anniversary of the discovery of Chagas disease, several campaigns denounced the scant progress has been made in diffrent spheres- medical, scientific and politcal- but major challanges still remain. This is an appropriate time to celebrate what has been ach...
Accessed on 22.04.2023
To target helminth elimination, a new consortium of research institutes, universities, not-for-profit organizations, and pharmaceutical companies have joined forces and expertise to establish a research and development pipeline for the development of anthelminthics targeti...
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease. Endemic in 21 Latin American countries, the disease can be transmitted by vector insects called triatomines — also known as “kissing bugs” —, foods or beverages contaminated with th...
J Glob Health Sci. 2020 Jun;2(1):e3. A group of enzootic and zoonotic protozoan infections, the leishmaniases constitute among the most severely neglected tropical diseases (NTDs) and are found in all continents except Oceania. Representing the most common infectious diseases, NTDs comprise an open-...
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...
The objectives of the meeting were:
1. To step up the commitment of national authorities and technical and financial partners toWHO’s elimination objective for g-HAT.
2. To share achievements, challenges and views on the elimination goal among countries and implementing partners.
3. To assess t...
On 9 February 2021, a first webinar entitled “Expanding our understanding of Post COVID-19 condition” was held under the auspices of WHO and in consultation with the International Severe Acute Respiratory and Emerging Infection Consortium(ISARIC), Global Research Collaboration for Infectious Dis...
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
Lessons from the STEP-TB Project.
Accessed November 2017.
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...
Meeting Report
27–30 June 2017 Manila, Philippines
Technology landscape
Rreport of a WHO Consultative Meeting Kolkata India 2012
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58
The present information document supplements the WHO audited financial statements for 2018. It contains information on WHO's voluntary contributions by fund and by contributor in the year 2018.
